Terms: = Liver cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1 AND Clinical Outcome
3 results:
1. Development of BRAF V600E Mutation in nras Q61L Mutated Rectal cancer.
Cao MN; Chen KT; Li QF; Wang L; Jin GW; Na RT; Ma J; Liu YT; Gao JL
Ann Clin Lab Sci; 2021 Mar; 51(2):262-266. PubMed ID: 33941568
[TBL] [Abstract] [Full Text] [Related]
2. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
[TBL] [Abstract] [Full Text] [Related]
3. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract] [Full Text] [Related]
